Correlation of tumor uptake on breast-specific gamma imaging and fluorodeoxyglucose PET/CT with molecular subtypes of breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Soo Jin | - |
dc.contributor.author | Chung, Min Sung | - |
dc.contributor.author | Shin, Su-Jin | - |
dc.contributor.author | Choi, Yun Young | - |
dc.date.accessioned | 2022-07-11T05:23:44Z | - |
dc.date.available | 2022-07-11T05:23:44Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2018-10 | - |
dc.identifier.issn | 0025-7974 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/149252 | - |
dc.description.abstract | Mechanisms of technetium-99m sesta-methoxyisobutylisonitrile (sestamibi) and F-18-fluorodeoxyglucose (FDG) uptake by tumor are different. The purpose of this study was to investigate the association between the tumor uptake of these 2 tracers in invasive ductal carcinoma and to examine thecorrelation of uptake of each tracer with prognostic factors and tumor molecular subtypes. A total of 96 patients with invasive ductal carcinoma who underwent preoperative breast-specific gamma imaging and FDG positron-emission tomography/computed tomography were retrospectively enrolled. Tumor-to-background ratio (TBR) of sestamibi and maximum standardized uptake value (SUVmax) of FDG were correlated with each other. Each of them was then compared with prognostic factors and molecular subtypes. In all tumors, there was a moderate positive correlation between TBR and SUVmax (r = 0.520, P < .001). Both TBR and SUVmax were significantly correlated with tumor size, incidence of axillary lymph node metastasis, histologic grade, estrogen receptor, progesterone receptor status, and Ki-67. There is a moderate degree of association between TBR of sestamibi and SUVmax of FDG in the invasive breast cancer. Two imaging indexes showed the similar tendency related with prognostic factors and molecular subtypes. While both TBR and SUVmax were significantly different between luminal A and nonluminal A tumors, neither of them had high enough sensitivity or specificity to obviate pathologic and molecular diagnosis. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.title | Correlation of tumor uptake on breast-specific gamma imaging and fluorodeoxyglucose PET/CT with molecular subtypes of breast cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Chung, Min Sung | - |
dc.contributor.affiliatedAuthor | Choi, Yun Young | - |
dc.identifier.doi | 10.1097/MD.0000000000012840 | - |
dc.identifier.scopusid | 2-s2.0-85056431044 | - |
dc.identifier.wosid | 000452441600018 | - |
dc.identifier.bibliographicCitation | MEDICINE, v.97, no.43 | - |
dc.relation.isPartOf | MEDICINE | - |
dc.citation.title | MEDICINE | - |
dc.citation.volume | 97 | - |
dc.citation.number | 43 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordAuthor | technetium-99m sesta-methoxyisobutylisonitrile | - |
dc.subject.keywordAuthor | breast cancer | - |
dc.subject.keywordAuthor | breast-specific gamma imaging | - |
dc.subject.keywordAuthor | breast-specific gamma imaging | - |
dc.subject.keywordAuthor | fluorodeoxyglucose | - |
dc.identifier.url | https://journals.lww.com/md-journal/Fulltext/2018/10260/Correlation_of_tumor_uptake_on_breast_specific.18.aspx | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.